KEYNOTE-057
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
- NCT02625961 ↗
- Terminated
- Merck Sharp & Dohme LLC
- Deep
We haven't built an HCP commentary report on KEYNOTE-057 (pembrolizumab, Pembrolizumab/vibostolimab coformulation and 1 more in Bladder Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-057 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 40 | |
| YouTube | 33 | |
| Podcasts | 31 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination With Other Investigational Agents in Subjects With High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab; Pembrolizumab/vibostolimab coformulation; Favezelimab/pembrolizumab coformulation
- Arms
- Pembrolizumab · Experimental
- Pembrolizumab coformulation · Experimental
- Enrollment
- 296
- Primary outcomes
- Cohort A: Complete Response (CR) Rate of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
- Cohort B: 12-month Disease-Free Survival (DFS) Rate of High-Risk NMIBC
- Cohort A and B: Number of Participants Who Experience an Adverse Event (AE)
- Cohort A and B: Number of Participants Who Discontinue Study Treatment Due to an AE
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Feb 10, 2016
- Primary completion
- Nov 5, 2025
- Results posted
- No
- Registry record
- NCT02625961 · updated Aug 31, 2026
Publications
linked from the registry- Necchi A, Roumiguie M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 Jun;25(6):720-730. doi: 10.1016/S1470-2045(24)00178-5. Epub 2024 May 10. PubMed 38740030
- Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. PubMed 34051177